Study of a new drug for cancer-related weight loss
Part of Cancer clinical trials.
This study tests a new drug called DS010 to see if it can help people with cancer-related weight loss and muscle loss (cachexia). The goal is to improve appetite and strength, which may help you feel better during cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed solid tumor cancer (such as lung, breast, or colon cancer).
- Your medical records must show cancer-related weight loss and muscle loss (cachexia).
- You should be able to care for yourself and be up and about at least part of the day (ECOG score 0, 1, or 2).
- You must not be on tube feeding or IV nutrition at the start of the study.
- You should not be in another clinical trial currently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new drug (AV-380) in people with solid tumor cancer who are losing weight and muscle because of cancer. It mainly helps researchers find a safe dose and see how the body responds, and it may offer a new option for cancer-related cachexia.
This study tests a special form of megestrol acetate (a medicine that can help with appetite and weight gain) in people with advanced digestive system cancers who are about to start or are already taking a type of targeted therapy called a TKI. The goal is to see if it helps with cancer-related weight loss and wasting (cachexia).
This study tests a new drug called GFS202A for people with advanced solid tumors who are experiencing weight loss or have a low body mass index (cachexia). The goal is to see if the drug is safe and can help improve appetite and weight.
This trial tests an investigational injection called INB301 to see if it can help reduce weight loss and improve appetite in people with cancer-related wasting (cachexia). It is a phase 1/2 study, so it is one of the first times the drug is given to people, and safety is a key goal.
This study tests a new medicine (QLS2319) to see if it’s safe and can help people with cancer-related weight loss and muscle loss (cachexia). It’s for people whose daily activities aren’t severely limited by their cancer.
This study tests whether a drug already approved for other cancers can help patients with advanced lung, pancreatic, or colorectal cancer who are losing weight. The drug may help improve appetite and weight stability.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.